Targeting neuronal lysosomal dysfunction caused by β-glucocerebrosidase deficiency with an enzyme-based brain shuttle construct
Alexandra Gehrlein (),
Vinod Udayar,
Nadia Anastasi,
Martino L. Morella,
Iris Ruf,
Doris Brugger,
Sophia Mark,
Ralf Thoma,
Arne Rufer,
Dominik Heer,
Nina Pfahler,
Anton Jochner,
Jens Niewoehner,
Luise Wolf,
Matthias Fueth,
Martin Ebeling,
Roberto Villaseñor,
Yanping Zhu,
Matthew C. Deen,
Xiaoyang Shan,
Zahra Ehsaei,
Verdon Taylor,
Ellen Sidransky,
David J. Vocadlo,
Per-Ola Freskgård and
Ravi Jagasia ()
Additional contact information
Alexandra Gehrlein: Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd
Vinod Udayar: Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd
Nadia Anastasi: Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd
Martino L. Morella: Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd
Iris Ruf: Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd
Doris Brugger: Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd
Sophia Mark: Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd
Ralf Thoma: Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd
Arne Rufer: Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd
Dominik Heer: Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd
Nina Pfahler: Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd
Anton Jochner: Roche Innovation Center Munich, Roche Diagnostics GmbH
Jens Niewoehner: Roche Innovation Center Munich, Roche Diagnostics GmbH
Luise Wolf: Data & Analytics, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd
Matthias Fueth: Pharmaceutical Science, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd
Martin Ebeling: Pharmaceutical Science, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd
Roberto Villaseñor: Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd
Yanping Zhu: Simon Fraser University
Matthew C. Deen: Simon Fraser University
Xiaoyang Shan: Simon Fraser University
Zahra Ehsaei: University of Basel
Verdon Taylor: University of Basel
Ellen Sidransky: National Human Genome Research Institute
David J. Vocadlo: Simon Fraser University
Per-Ola Freskgård: Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd
Ravi Jagasia: Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd
Nature Communications, 2023, vol. 14, issue 1, 1-21
Abstract:
Abstract Mutations in glucocerebrosidase cause the lysosomal storage disorder Gaucher’s disease and are the most common risk factor for Parkinson’s disease. Therapies to restore the enzyme’s function in the brain hold great promise for treating the neurological implications. Thus, we developed blood-brain barrier penetrant therapeutic molecules by fusing transferrin receptor-binding moieties to β-glucocerebrosidase (referred to as GCase-BS). We demonstrate that these fusion proteins show significantly increased uptake and lysosomal efficiency compared to the enzyme alone. In a cellular disease model, GCase-BS rapidly rescues the lysosomal proteome and lipid accumulations beyond known substrates. In a mouse disease model, intravenous injection of GCase-BS leads to a sustained reduction of glucosylsphingosine and can lower neurofilament-light chain plasma levels. Collectively, these findings demonstrate the potential of GCase-BS for treating GBA1-associated lysosomal dysfunction, provide insight into candidate biomarkers, and may ultimately open a promising treatment paradigm for lysosomal storage diseases extending beyond the central nervous system.
Date: 2023
References: View references in EconPapers View complete reference list from CitEc
Citations:
Downloads: (external link)
https://www.nature.com/articles/s41467-023-37632-4 Abstract (text/html)
Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.
Export reference: BibTeX
RIS (EndNote, ProCite, RefMan)
HTML/Text
Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:14:y:2023:i:1:d:10.1038_s41467-023-37632-4
Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/
DOI: 10.1038/s41467-023-37632-4
Access Statistics for this article
Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie
More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().